**PS20-2010 Ending the HIV Epidemic**

Evaluation and Performance Measurement Plan (EPMP) and
 Work Plan: Component B - HIV Incidence Surveillance



**Name of Jurisdiction/Agency Submitting Plan**: Click to enter text.

**Point of Contact for Correspondence**: Click to enter text.

**Mailing Address**: Click to enter text.

**Email**: Click to enter text.

**Phone**: Click to enter text.

**Fax**: Click to enter text.

**Point of Contact for Evaluation**: Click to enter text.

**Mailing Address**: Click to enter text.

**Email**: Click to enter text.

**Phone**: Click to enter text.

**Fax**: Click to enter text.

**Project Period**: TBD

**Last Updated Date**: Click to enter a date.

**Version B1.0**

Note: PS20-2010 EPMP Version B1.0 applies to Component B and should not be completed for Component A or Component C.

Table of Contents

[**I.** **Program Description** – **Component B** 2](#_Toc29883371)

[Section 1: Logic Model – Component B 2](#_Toc29883372)

[Section 2: Program Activities – Component B 3](#_Toc29883373)

[Section 3: Priority Populations – Component B 3](#_Toc29883374)

[**II.** **Jurisdiction Evaluation Plan** – **Component B** 4](#_Toc29883375)

[Section 5: Proposed Activities and Indicators 4](#_Toc29883376)

[Section 6: Data Management Plan (DMP) – Component B 9](#_Toc29883377)

[Section 7: Human Subjects 10](#_Toc29883378)

[**III.** **Standards, Targets, and Local Objectives** – **Component B** 11](#_Toc29883379)

[Section 9: EHE Targets and Jurisdiction Objectives – Component B 11](#_Toc29883380)

[**IV.** **Appendix A: Logic Model** 12](#_Toc29883381)

# **Program Description** – **Component B**

## Section 1: Logic Model – Component B

Please provide a logic model for PS20-2010 Component B that reflects the relationships between your project’s strategies and outcomes.

**Note**: You may adopt the CDC logic model (refer to Appendix A) for your local PS20-2010 Component B program without modification. However, if you wish to include more detail in your logic model for your jurisdiction, please do so below. **Section 1 need not be completed if the jurisdiction has adopted the CDC logic model – Component B (Appendix A).**

| **PS20-2010 Component B Logic Model – Ending the HIV Epidemic** |
| --- |
| **Strategy** | **Short-Term Outcome** | **Intermediate Outcome** | **Long-Term Outcome** |
|  |

|  |
| --- |
| Strategy B1: Work with stakeholders to identify best practices for implementing a recency-based HIV incidence surveillance.  |

 |  |  |  |
|  |

|  |
| --- |
| Strategy B2: Conduct recency-based HIV incidence surveillance in selected jurisdictions.  |

 |  |  |  |
|  |

|  |
| --- |
| Strategy B3: Review incidence results from a CD4 depletion model and a recency-based assay model.  |

 |  |  |  |

## Section 2: Program Activities – Component B

In the table below, please provide a description of the program activities to be implemented under PS20-2010 Component B. Activities described in this section should align with the strategies and outcomes noted in the logic model provided in Appendix A (and Section 1, if applicable). Your description for PS20 2010 Year 2 (project year 1) should be a summary and should convey enough detail to ensure the understanding of program goals and activities (note: this should not be a copy/paste of program activities from the application.) Your description of PS20 2010 Component B Year 2-4 should be high-level summary of the activities.

**Note:** If you need assistance, please contact your PS20-2010 CDC Joint Monitoring Team (JMT).

| PS20-2010 Component B: HIV Incidence Surveillance |
| --- |
| **Strategy** | **Activity** |
| **PS20 2010** **Year 2** | **PS20 2010** **Year 3-5** |
| Strategy B1: Work with stakeholders to identify best practices for implementing a recency-based HIV incidence surveillance. |  |  |
| Strategy B2: Conduct recency-based HIV incidence surveillance in selected jurisdictions |  |  |
| Strategy B3: Review incidence results from a CD4 depletion model and a recency-based assay model |  |  |

## Section 3: Priority Populations – Component B

The target population for this component is persons with newly diagnosed HIV infection, including racial/ethnic and sexual minorities. In Table 1 below, please describe strategies to ensure the collection of relevant surveillance data for the population targeted

|  |
| --- |
| **Table 1. Priority and Target Populations** |
| **Priority Population** | **Identification in Integrated Care and Prevention Plan (i.e., page numbers)** | **Identified Need** | **Primary Strategies & Activities to Address Need** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

# **Jurisdiction Evaluation Plan** – **Component B**

## Section 5: Proposed Activities and Indicators

The indicators and specifications provided in section 5 are to be used for Component B activities. Please note the activities listed below are examples of what your program may opt to perform.

|  |
| --- |
| **PS20-2010 Component B - HIV Incidence Surveillance - Year 2** |
| **Activity**  | **Indicator** | **Specification** | **Data Reported to CDC**  |
| Strategy B1: Work with stakeholders to identify best practices for implementing a recency-based HIV incidence surveillance. |
|[ ]  B.1.1. Engage a diverse group of key partners, stakeholders, and community members prior to implementing activities and continue as an ongoing process | Documentation of engagement with a diverse group of key partners, stakeholders, and community members prior to implementing activities and continue as an ongoing process | Description of efforts to engage a diverse group of key partners, stakeholders, and community members prior to implementing activities and continue as an ongoing process | Data reported from HD through APRFrequency: Annually |
|  |  |  | **Count:** Number of meetings held with key partners, stakeholders, and community members prior to implementing activities and on an annual basis |  |

|  |
| --- |
|  |
| **PS20-2010 Component B - HIV Incidence Surveillance - Year 2** |
| **Activity** | **Indicator** | **Specification** | **Data Reported to CDC** |
| Strategy B2: Conduct recency-based HIV incidence surveillance in selected jurisdictions |
|[ ]  B.2.1. Secure remnant specimens from the original diagnostic HIV test or other HIV-related test performed within one month of diagnosis by public or private laboratories (within and outside the state) |

|  |
| --- |
| Increased capacity to collect recency-based assay results from all persons aged 13 years and older with a new diagnosis of HIV  |

 | **Numerator:** Number of eligible persons aged 13 years and older with a new diagnosis of HIV that have a recency result | NHSSFrequency: Annually |
|  |  |  | **Denominator:** Number of eligible persons aged 13 years and older with a new diagnosis of HIV |  |
|  | B.2.2. Coordinate with public and private HIV testing laboratories (within and outside the state) to arrange transport of remnant specimens to a selected laboratory for storage and eligibility assessment  | Identification of laboratories within and outside state that perform diagnostic HIV tests or other HIV-related tests for persons residing in jurisdiction | **Count:** Number of laboratories within and outside state that perform diagnostic HIV tests or other HIV-related tests for persons residing in jurisdiction | Data reported from HD Frequency: Annually |
|  |  | Participation of identified HIV testing laboratories in HIV incidence surveillance activities | **Numerator:** Number of identified HIV testing laboratories that participate in HIV incidence surveillance activities | Data reported from HD Frequency: Annually  |
|  |  |  | **Denominator:** Number of laboratories within and outside state that perform diagnostic HIV tests or other HIV-related tests for persons in jurisdiction |  |
|[ ]  B.2.3 Identify and locate specimens eligible for recency testing for persons with newly diagnosed HIV that are reported to the state or local surveillance system and inform the appropriate laboratory of the need to ship specimens to the laboratory designated by CDC for recency testing. Establish procedures for tracking specimen shipments as well as receipt of recency testing results from the CDC-designated laboratory and results submission to the National HIV Surveillance System.  | Documentation of procedures for tracking specimen shipments as well as receipt of recency testing results from the CDC-designated laboratory | Documentation of procedures for tracking specimen shipments as well as receipt of recency testing results from the CDC-designated laboratory | Reported from HD Frequency: Annually |
|  |  | Percentage of specimens eligible for recency testing from persons with newly diagnosed HIV that are shipped to the CDC-designated laboratory for recency testing | **Numerator:** Number of eligible specimens shipped to CDC-designated laboratory for recency testing | Data reported from HD Frequency: Annually  |
|  |  |  | **Denominator:** Number of specimens eligible for recency testing  |  |

|  |
| --- |
|  |
| **PS20-2010 Component B - HIV Incidence Surveillance - Year 2** |

|  |  |  |  |
| --- | --- | --- | --- |
| **Activity** | **Indicator** | **Specification** | **Data Reported to CDC** |
| Strategy B3: Review incidence results from a CD4 depletion model and a recency-based assay model |
|  | B.3.1. Ensure integration of HIV incidence surveillance with routine HIV surveillance activities | Documentation of integration of HIV incidence surveillance with routine HIV surveillance activities | Documentation of integration of HIV incidence surveillance with routine HIV surveillance activities | Reported from HD Frequency: Annually |
|  | B.3.2. Collect RITA results for incidence estimation | Percentage of persons age 13 years and older with a new diagnosis of HIV that have RITA results for incidence estimation | **Numerator:** Number persons aged 13 years and older with a new diagnosis of HIV that have a RITA result**Denominator**: Number of persons aged 13 years and older with a new diagnosis of HIV | NHSSFrequency: Annually  |
|  | B.3.2. Collect HIV testing history information (e.g., dates, tests used, results) | Percentage of persons age 13 years and older with a new diagnosis of HIV that have a usable value (as defined in CDC technical guidance) for any HIV testing history information for incidence estimation | **Numerator:** Number of persons aged 13 years and older with a new diagnosis of HIV that have a usable value (as defined in CDC technical guidance) for any HIV testing history information for incidence estimation | NHSSFrequency: Annually  |
| **Denominator:** Number of persons aged 13 years and older with a new diagnosis of HIV  |
|  | B.3.3. Collect antiretroviral (ARV) drug exposure history (including for treatment, for pre- or post-exposure prophylaxis, or for any other purpose/reason) | Percentage of persons age 13 years and older with a new diagnosis of HIV that have ARV drug exposure history information  | **Numerator:** Number of persons aged 13 years and older with a new diagnosis of HIV that have ARV drug exposure history information | NHSSFrequency: Annually |
| **Denominator:** Number of persons aged 13 years and older with a new diagnosis of HIV  |
|  | B.3.4. Collect viral load results from specimens within 1 month after diagnosis (ideally from the same specimen as the diagnostic remnant specimen for RITA) to confirm the presence of untreated HIV infection | Percentage of persons aged 13 years and older with a new diagnosis of HIV that have a viral load result from a specimen within 1 month after diagnosis | **Numerator:** Number of persons aged 13 years and older with a new diagnosis of HIV that have a viral load result from a specimen within 1 month after diagnosis | NHSSFrequency: Annually |
| **Denominator:** Number of persons aged 13 years and older with a new diagnosis of HIV  |
|  | B.3.5. Submit data to CDC | Monthly submission of HIV case and incidence surveillance data  | **Count:** Number of annual data transfers | NHSSFrequency: Annually |
|  | B.3.6. Comply with security and confidentiality standards | Documentation of compliance with security and confidentiality standards | Documentation of compliance with security and confidentiality standards | Reported from HD Frequency: Annually |
|  | B.3.7. Conduct systematic data quality and evaluation activities | Documentation of systematic data quality and evaluation activities | Documentation of systematic data quality and evaluation activities | Reported from HD Frequency: Annually |
| [ ]  | B.3.8. Calculate and disseminate routine population-based HIV incidence estimates | Calculation of estimated HIV incidence in selected jurisdictions using a recency-based assay | CDC-developed model and related analytic program for local use | NHSS and local eHARS/Copies of or links to locally/HD-produced and disseminated reports Frequency: Annually |
| Documentation of activities and reports produced to disseminate routine population-based HIV incidence estimates | Documentation of activities and reports produced to disseminate routine population-based HIV incidence estimates |

## Section 6: Data Management Plan (DMP) – Component B

Please ensure that personally identifiable information (PII) is appropriately collected, processed, stored, and protected to maintain compliance with public laws, federal regulations, and executive orders.

**Note**: The management, security, and confidentiality of data for the PS20-2010 Component B project should be addressed and updated in the PS20-2010 Component B DMP. The DMP must be updated annually or when any significant change is made to a data set or system to ensure that the DMP remains current throughout the lifecycle of the project.

|  |  |
| --- | --- |
| **Elements** | **Surveillance Data** |
| Description of data collected and standards used. Include information on data sources or other databases if used (e.g., conforms to standards outlined in CDC technical guidance for HIV surveillance).  |  |
| Data steward(s)  |  |
| Mechanisms for within-agency limiting or sharing of data and justifications (e.g., data sharing agreements and process for using them) |  |
| Mechanisms for sharing data with partners (e.g., CPG, Ryan White) |  |
| Description of data release policies and procedures including precautions to protect confidentiality (e.g., data suppression criteria, other restrictions).  |  |
| Mechanisms for making data available to the public (e.g., reports, epi profile, datasets, CDC Atlas plus). Include description of prerelease data quality reviews and validation, data suppression checks. Address access to identifiable and de-identified data. |  |
| Statement that procedures are in place to ensure all released data have appropriate documentation and any limitations described.  |  |
| Description of steps taken to protect privacy and ensure confidentiality and security of data. Refer to applicable policies and statement signed by the overall responsible party (ORP) certifying program compliance with the NCHHSTP Guidelines  |  |
| Description of data archiving policies or provide explanation for why long-term preservation and access are not required.  |  |

**Add any additional notes here:**

Click to enter text.

## Section 7: Human Subjects

Please place an “X” in the appropriate box to indicate whether or not a Human Subjects Protection/Institutional Review Board approval is needed for any aspects of your non-research project.

|  |  |
| --- | --- |
| Yes |  |
| No |  |

# **Standards, Targets, and Local Objectives** – **Component B**

## Section 9: EHE Targets and Jurisdiction Objectives – Component B

Please insert your yearly objectives (local targets) for the key indicators in Table 5 below.

|  |
| --- |
| **Table 5. EHE Targets and Jurisdiction Objectives** |
| **Activity** | **Outcome** | **Indicator** | **Local Program Objectives** |
| **Baseline** | **PS20-2010** **Yr 1** | **PS20-2010****Yr 2** | **PS20-2010****Yr 3** | **PS20-2010****Yr 4** | **PS20-2010****Yr 5** |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

# **Appendix A: Logic Model**

Below is the CDC logic model for PS20-2010 Component B, including strategies, short-term and intermediate outcomes.

You may adopt this logic model for your local PS20-2010 Component B program without modification. However, if you wish to include more detail in your logic model, please use the space in Section 1 to describe any additional activities.

Note: PS20-2010 EPMP Version B1.0 applies to Component B and should not be completed for Component A or Component C.

|  |
| --- |
| **Component B: HIV Incidence Surveillance** |
| **PS20-2010 Logic Model – Ending the HIV Epidemic** |
| **Strategies** | **Short-Term Outcomes** | **Intermediate Outcomes** |
|  | * Work with stakeholders (e.g., community, laboratories, and providers) to identify best practices for implementing a recency-based incidence surveillance
* Conduct recency-based HIV incidence surveillance in selected jurisdictions
* Review incidence results from a CD4 depletion model and a recency-based assay model
 | * Improved coordination with stakeholders including community, laboratory, and clinical providers to develop recency-based incidence surveillance
* Increased capacity to collect recency-based assays from all persons aged 13 years and older with a new HIV diagnosis
 | * **Estimate HIV incidence in selected jurisdictions using a recency-based assay**
* Review HIV incidence using a CD4 depletion model and a recency-based assay model
 |